QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED - Company Information

Print Friendly Version

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Company Registration Number:
11562019 (England and Wales)

Unaudited abridged accounts for the year ended 09 March 2022

Period of accounts

Start date: 10 March 2021

End date: 09 March 2022

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Contents of the Financial Statements

for the Period Ended 09 March 2022

Balance sheet
Notes

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Balance sheet

As at 09 March 2022


Notes
2022
2021


£
£
Called up share capital not paid: 0 0
Fixed assets
Intangible assets:   0 0
Tangible assets:   0 0
Investments:   0 0
Total fixed assets: 0 0
Current assets
Stocks: 0 0
Debtors: 3 223,864 227,943
Cash at bank and in hand: 0 0
Investments:   0 0
Total current assets: 223,864 227,943
Creditors: amounts falling due within one year: 4 (307,828) (308,157)
Net current assets (liabilities): (83,964) (80,214)
Total assets less current liabilities: (83,964) (80,214)
Creditors: amounts falling due after more than one year:   0 0
Provision for liabilities: 0 0
Total net assets (liabilities): (83,964) (80,214)
Capital and reserves
Called up share capital: 100 100
Share premium account: 0 0
Revaluation reserve: 00
Other reserves: 22,228,607 22,228,607
Profit and loss account: (22,312,671) (22,308,921)
Shareholders funds: (83,964) (80,214)

The notes form part of these financial statements

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Balance sheet statements

For the year ending 9 March 2022 the company was entitled to exemption under section 477 of the Companies Act 2006 relating to small companies.

The members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Act with respect to accounting records and the preparation of accounts.

The members have agreed to the preparation of abridged accounts for this accounting period in accordance with Section 444(2A).

These accounts have been prepared in accordance with the provisions applicable to companies subject to the small companies regime.

The directors have chosen to not file a copy of the company’s profit & loss account.

This report was approved by the board of directors on 15 November 2022
and signed on behalf of the board by:

Name: Axel Backheuer
Status: Director

The notes form part of these financial statements

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Notes to the Financial Statements

for the Period Ended 09 March 2022

1. Accounting policies

These financial statements have been prepared in accordance with the provisions of Section 1A (Small Entities) of Financial Reporting Standard 102

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Notes to the Financial Statements

for the Period Ended 09 March 2022

2. Employees

2022 2021
Average number of employees during the period 0 0

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Notes to the Financial Statements

for the Period Ended 09 March 2022

3. Debtors

2022 2021
££
Debtors due after more than one year: 0 0

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Notes to the Financial Statements

for the Period Ended 09 March 2022

4. Creditors: amounts falling due within one year note

VAT Payable £220,834Amounts due to fellow subsidiary undertakings £86,994

QIAGEN HEALTHCARE BIOTECHNOLOGIES SYSTEMS LIMITED

Notes to the Financial Statements

for the Period Ended 09 March 2022

5. Related party transactions

As the company is a wholly owned subsidiary of QIAGEN N.V., the company has taken advantage of the exemption contained in Financial Reporting Standard 102 and has therefore not disclosed transactions or balances with wholly owned members of the group. The group financial statements of QIAGEN N.V., within which this company is included, can be obtained from the company’s registered address.